Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

SIOG 2014 /
Older patients benefit from lower doses of sunitinib in renal cell carcinoma

23rd - 25th Oct 2014

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 10.11.14
Views: 2133

Dr Ravindran Kanesvaran - National Cancer Centre Singapore, Singapore

"We must dispel this concept of ageism," Dr Kanesvaran tells ecancertv at SIOG 2014. He discusses his study on sunitinib in metastatic renal cell carcinoma, which found that patients benefit from a lower dose.

Older patients may particularly benefit from starting treatment at lowered doses.


Elderly · Complications · Cytotoxics · SIOG 2014

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation